CA2909921C - Synthetic library of specific binding molecules - Google Patents

Synthetic library of specific binding molecules Download PDF

Info

Publication number
CA2909921C
CA2909921C CA2909921A CA2909921A CA2909921C CA 2909921 C CA2909921 C CA 2909921C CA 2909921 A CA2909921 A CA 2909921A CA 2909921 A CA2909921 A CA 2909921A CA 2909921 C CA2909921 C CA 2909921C
Authority
CA
Canada
Prior art keywords
cdr3
sequences
library
sequence
vnar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909921A
Other languages
English (en)
French (fr)
Other versions
CA2909921A1 (en
Inventor
Caroline Jane BARELLE
William James Jonathan Finlay
Alfredo DARMANIN-SHEEHAN
Andrew Justin Radcliffe Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elasmogen Ltd
Original Assignee
Elasmogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elasmogen Ltd filed Critical Elasmogen Ltd
Publication of CA2909921A1 publication Critical patent/CA2909921A1/en
Application granted granted Critical
Publication of CA2909921C publication Critical patent/CA2909921C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
CA2909921A 2013-04-23 2014-04-23 Synthetic library of specific binding molecules Active CA2909921C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361815043P 2013-04-23 2013-04-23
US61/815,043 2013-04-23
PCT/EP2014/058251 WO2014173959A2 (en) 2013-04-23 2014-04-23 Synthetic library of specific binding molecules

Publications (2)

Publication Number Publication Date
CA2909921A1 CA2909921A1 (en) 2014-10-30
CA2909921C true CA2909921C (en) 2022-12-06

Family

ID=50543598

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2909921A Active CA2909921C (en) 2013-04-23 2014-04-23 Synthetic library of specific binding molecules
CA2909923A Abandoned CA2909923A1 (en) 2013-04-23 2014-04-23 Isolation of therapeutic target specific vnar domains to icosl

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2909923A Abandoned CA2909923A1 (en) 2013-04-23 2014-04-23 Isolation of therapeutic target specific vnar domains to icosl

Country Status (11)

Country Link
US (3) US10472410B2 (enExample)
EP (3) EP2989203B1 (enExample)
JP (2) JP6591964B2 (enExample)
KR (2) KR20160010466A (enExample)
CN (2) CN105492610B (enExample)
AU (3) AU2014257549B2 (enExample)
BR (2) BR112015026729A2 (enExample)
CA (2) CA2909921C (enExample)
DK (1) DK2989203T3 (enExample)
RU (2) RU2015146418A (enExample)
WO (2) WO2014173959A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151658A1 (en) 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule
US10472410B2 (en) 2013-04-23 2019-11-12 The University Court Of The University Of Aberdeen Isolation of therapeutic target specific VNAR domains to ICOSL
CA2953569A1 (en) 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
CN107074961A (zh) * 2014-11-03 2017-08-18 默克专利股份公司 用于生成双特异性鲨鱼可变抗体结构域的方法及其用途
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
KR20250095754A (ko) 2016-04-15 2025-06-26 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
CN107130300A (zh) * 2016-10-08 2017-09-05 深圳劲宇生物科技有限公司 一种dna编码分子库的合成方法及dna模板
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
KR102657978B1 (ko) 2017-09-27 2024-04-16 엘라스모겐 리미티드 특이적 결합 분자
US11180544B2 (en) * 2017-11-07 2021-11-23 City University Of Hong Kong Method of producing antibody fragment
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
CN111197074B (zh) * 2018-11-20 2023-08-15 深圳华大生命科学研究院 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用
WO2020167872A1 (en) * 2019-02-11 2020-08-20 Woodbury Neal W Systems, methods, and media for molecule design using machine learning mechanisms
GB201906997D0 (en) * 2019-05-17 2019-07-03 Elasmogen Ltd Conjugates
GB201908886D0 (en) * 2019-06-20 2019-08-07 Almac Discovery Ltd Anthracycline derivatives
JP7765090B2 (ja) * 2020-05-01 2025-11-06 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ナノボディ及びナノボディ親和性を同定するための組成物及び方法
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
GB202020154D0 (en) * 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
GB202020152D0 (en) 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ES2458636T3 (es) * 2003-08-18 2014-05-06 Medimmune, Llc Humanización de anticuerpos
EP2261332A3 (en) * 2003-08-27 2012-05-09 Proterec Ltd Libraries of recombinant chimeric proteins
EP1751181B1 (en) 2004-06-02 2012-08-15 AdAlta Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
US7728114B2 (en) * 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
WO2006003999A1 (ja) 2004-07-05 2006-01-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
EP2368993A3 (en) 2005-03-25 2012-06-13 National Research Council Of Canada Method for isolation of soluble polypeptides
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
EA021669B1 (ru) 2005-07-18 2015-08-31 Амджен Инк. Нейтрализующие антитела человека против b7rp1
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
CN101528767A (zh) 2006-10-11 2009-09-09 埃博灵克斯股份有限公司 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途
WO2009026638A1 (en) 2007-08-31 2009-03-05 Melbourne Health Marine-animal derived therapeutic and diagnostic agents for hepatitis b
EP2344545A4 (en) * 2008-10-06 2012-10-03 Commw Scient Ind Res Org CRYSTALLINE STRUCTURE OF BETA-AMYLOID PEPTIDE
CA2738801A1 (en) * 2008-10-07 2010-04-15 Zap Holdings Limited Synchronization of relational databases with olap cubes
US8496933B2 (en) 2009-11-04 2013-07-30 Laboratorios Silanes, S.A. De C.V. VHNAR anti-cytokine domains
US20140154241A1 (en) * 2010-12-03 2014-06-05 Cyclogenix Ltd Binding peptides i
EP4151658A1 (en) 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule
CN103031304A (zh) * 2012-12-27 2013-04-10 苏州大学 一种微小rna用于调控b7-h2基因表达
US10472410B2 (en) 2013-04-23 2019-11-12 The University Court Of The University Of Aberdeen Isolation of therapeutic target specific VNAR domains to ICOSL

Also Published As

Publication number Publication date
WO2014173959A3 (en) 2015-01-29
EP2989204A1 (en) 2016-03-02
KR102320189B1 (ko) 2021-11-03
RU2015146418A3 (enExample) 2018-05-07
CN105531370A (zh) 2016-04-27
EP2989204B1 (en) 2019-03-20
US10472410B2 (en) 2019-11-12
EP3683312A2 (en) 2020-07-22
JP6616284B2 (ja) 2019-12-04
US20160176951A1 (en) 2016-06-23
BR112015026716A2 (pt) 2017-09-05
WO2014173959A2 (en) 2014-10-30
DK2989203T3 (da) 2020-02-17
KR20160010466A (ko) 2016-01-27
RU2015146419A (ru) 2017-05-26
EP3683312A3 (en) 2020-09-16
US11459377B2 (en) 2022-10-04
EP2989203A2 (en) 2016-03-02
CA2909923A1 (en) 2014-10-30
CN105492610A (zh) 2016-04-13
EP2989203B1 (en) 2019-11-13
AU2019206064A1 (en) 2019-08-08
US10202438B2 (en) 2019-02-12
RU2015146418A (ru) 2017-05-26
EP3683312B1 (en) 2022-09-07
AU2014257549A1 (en) 2015-11-26
US20160068600A1 (en) 2016-03-10
WO2014173975A1 (en) 2014-10-30
KR20160015220A (ko) 2016-02-12
US20200002403A1 (en) 2020-01-02
CA2909921A1 (en) 2014-10-30
AU2014257549B2 (en) 2019-04-18
JP2016524592A (ja) 2016-08-18
JP2016524463A (ja) 2016-08-18
BR112015026729A2 (pt) 2017-09-05
CN105492610B (zh) 2020-08-25
JP6591964B2 (ja) 2019-10-16
AU2014257565A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
US11459377B2 (en) Synthetic library of specific binding molecules
CN108473987B (zh) 具有改变的多样性支架结构域的结合成员
EP4177267A1 (en) Anti-surrogate light chain antibodies
JP2021518168A (ja) 拮抗的抗原結合タンパク質
US20240376639A1 (en) Fast-track humanisation of specific binding molecules
CN120865416B (zh) 抗mica/b抗体及其应用
HK40090806A (en) Anti-surrogate light chain antibodies
CN120157769A (zh) 一种新型环肽构型、其文库制备方法及应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190417

EEER Examination request

Effective date: 20190417

EEER Examination request

Effective date: 20190417